Argyrophilia and chromogranin A and B immunostaining in patients with sporadic medullary thyroid carcinoma. A critical appraisal of their prognostic utility

Journal of Pathology

Volumn 184, Issue 4, 1998, Pages 414-419

  Scopsi, Lucio ^a,c   Sampietro, Giuseppe ^a   Boracchi, Patrizia ^b   Collini, Paola ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c NONE   (Italy)

Author keywords

Argyrophilia; Chromogranin; Immunocytochemistry; Prognos is; Secretogranin; Thyroid medullary carcinoma

Indexed keywords

CHROMOGRANIN A; CHROMOGRANIN B;

ARGYROPHILIA; ARTICLE; CANCER SURVIVAL; CELL DIFFERENTIATION; DATA ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STEM CELL; THYROID MEDULLARY CARCINOMA;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; CARCINOMA, MEDULLARY; CHROMOGRANIN A; CHROMOGRANINS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; PROGNOSIS; SILVER STAINING; SURVIVAL RATE; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0031894426     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199804)184:4<414::AID-PATH1229>3.0.CO;2-U     Document Type: Article

References (20)

1. Huttner WB, Gerdes H, Rosa P. The granin (chromogranin/secretogranin) family. Trends Biochem Sci 1991; 16: 27-30.
2. Schmid KW, Fischer-Colbrie R, Hagn C, Jasani B, Williams ED, Winkler H. Chromogranin A and B and secretogranin II in medullary carcinomas of the thyroid. Am J Surg Pathol 1987; 11: 551-556.
3. Hanna FWF, Ardill JES, Johnston CF, et al. Regulatory peptides and other neuroendocrine markers in medullary carcinoma of the thyroid. J Endocrinol 1997; 152: 275-281.
4. Sekiya K, Ghatei MA, Salahuddin MJ, et al. Production of GAWK (chromogranin-B 420-493)-like immunoreactivity by endocrine tumors and its possible diagnostic value. J Clin Invest 1989; 83: 1834-1842.
5. Lloyd RV, Iacangelo A, Eiden LE, Cano M, Jin L, Grimes M. Chromogranin A and B messenger ribonucleic acids in pituitary and other normal and neoplastic human endocrine tissues. Lab Invest 1989; 60: 548-556.
6. Dottorini ME, Assi A, Sironi M, Sangalli G, Spreafico G, Colombo L. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer 1996; 77: 1556-1565.
7. Schröder S, Böcker W, Baisch H, et al. Prognostic factors in medullary thyroid carcinomas. Survival in relation to age, sex, stage, histology, immunocytochemistry, and DNA content. Cancer 1988; 61: 806-816.
8. Viale G, Roncalli M, Grimelius L, et al. Prognostic value of bcl-2 immunoreactivity in medullary thyroid carcinoma. Hum Pathol 1995; 26: 945-950.
9. Scopsi L, Sampietro G, Boracchi P, et al. Multivariate analysis of prognostic factors in patients with sporadic medullary carcinoma of the thyroid. A retrospective study of 109 consecutive patients. Cancer 1996; 78: 2173-2183.
10. Grimelius L. A silver nitrate strain for alpha2-cells in human pancreatic islets. Acta Soc Med Upsal 1968; 73: 243-270.
11. Scopsi L, Gullo M, Rilke F, Martin S, Steiner F. Proprotein convertases (PC1/PC3 and PC2) in normal and neoplastic human tissues: their use as markers of neuroendocrine differentiation. J Clin Endocrinol Metab 1995; 80: 294-301.
12. Spiessl B, Beahrs OH, Hermanek P, et al. TNM Atlas. Illustrated Guide to TNM/pTNM Classification of Malignant Tumors. 3rd edn. 2nd rev. Berlin: Springer-Verlag, 1992.
13. Harach HR, Wilander E, Grimelius L, Bergholm U, Westermark P, Falkmer S. Chromogranin A immunoreactivity compared with argyrophilia, calcitonin immunoreactivity, and amyloid as tumour markers in the histopathological diagnosis of medullary (C-cell) thyroid carcinoma. Pathol Res Pract 1992; 188: 123-130.
14. Sikri KL, Varndell IM, Hamid QA, et al. Medullary carcinoma of the thyroid. An immunocytochemical and histochemical study of 25 cases using eight separate markers. Cancer 1985; 56: 2481-2491.
15. Bergholm U, Adami H-O, Auer G, et al. Histopathologic characteristics and nuclear DNA content as prognostic factors in medullary thyroid carcinoma. Cancer 1989; 64: 135-142.
16. Kimura N, Sasano N, Yamada R, Satoh J. Immunohistochemical study of chromogranin in 100 cases of pheochromocytoma, carotid body tumour, medullary thyroid carcinoma and carcinoid tumour. Virchows Arch A [Pathol Anat] 1988; 413: 33-38.
17. Mizukami Y, Nonomura A, Michigishi T, et al. Medullary thyroid carcinoma experienced at Kanazawa University Hospital. J Surg Oncol 1996; 61: 27-33.
18. Garcia A, Martin F, Garcia CF, Cavanzo FJ. Medullary carcinoma of the thyroid in Colombia: an immunohistochemical and clinicopathological study of 26 cases. Surg Pathol 1990; 3: 19-29.
19. Schmid KW, Kirchmayr R, Ladurner D, Fischer-Colbrie R, Böcker W. Immunohistochemical comparison of chromogranins A and B and secretogranin II with calcitonin and calcitonin gene-related peptide expression in normal, hyperplastic and neoplastic C-cells of the human thyroid. Histopathology 1992; 21: 225-232.
20. Blind E, Schmidtgayk H, Sinn HP, O'Connor DT, Raue F. Chromogranin-A as tumor marker in medullary thyroid carcinoma. Thyroid 1992; 2: 5-10.